ArticleACS applied materials & interfaces2026
Organic Electrochemical Transistors for Real-Time Detection of Immune System Early Activation during Atezolizumab-Bevacizumab Treatment in Hepatocellular Carcinoma.
Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly(3,4-ethylenedioxythiophene):polystyrenesulfonate (PEDOT:PSS)-based organic electrochemical transistors (OECTs) have been demonstrated as versatile biosensors in recent years. Owing to the biocompatibility and chemical stability of the organic mixed ionic and electronic conductor in cell media, they allow real-time, in vitro electrical monitoring of cell lines, providing quantitative outcomes of their health status. Here, we propose and validate a sensitive OECT device for direct in vitro monitoring of peripheral blood mononuclear cell (PBMC) activity in a coculture assay. PBMCs from patients with advanced hepatocellular carcinoma (HCC) responding and nonresponding to atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) are cocultured with Huh7 and SNU449 HCC cell lines directly grown onto OECTs. A strong correlation between the OECT electrical response, standard cell growth, death assays, and IL6 levels is observed, which is confirmed for cocultures involving PBMCs from healthy controls and patients treated with immunosuppressive drugs (namely, positive and negative controls, respectively). Our low-cost and scalable device has the potential to detect PBMC activation induced by atezolizumab-bevacizumab in the very early stages of HCC treatment, allowing for nonresponders' inclusion in alternative treatments. This approach might be of great interest to several human cancers treated with immune checkpoint inhibitors (ICIs), providing sensitive, automated, and noninvasive tools to complement clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.